Selected article for: "antiviral therapy and severe case"
Author: Bahrami, Afsane; Ferns, Gordon A
Title: Genetic and pathogenic characterization of SARS-CoV-2: a review
  • Cord-id: t7akdu6x
  • Document date: 2020_8_26
    • ID: t7akdu6x
    Snippet: The first case of Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in December 2019. This virus belongs to the beta-coronavirus group that contains a single stranded RNA with a nucleoprotein within a capsid. SARS-CoV-2 shares 80% nucleotide identity to SARS-CoV. The virus is disseminated by its binding to the ACE2 receptors on bronchial epithelial cells. The diagnosis of COVID-19 is based on a laboratory-based reverse transcr
    Document: The first case of Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in December 2019. This virus belongs to the beta-coronavirus group that contains a single stranded RNA with a nucleoprotein within a capsid. SARS-CoV-2 shares 80% nucleotide identity to SARS-CoV. The virus is disseminated by its binding to the ACE2 receptors on bronchial epithelial cells. The diagnosis of COVID-19 is based on a laboratory-based reverse transcription polymerase chain reaction (RT-PCR) test together with chest computed tomography imaging. To date, no antiviral therapy has been approved, and many aspects of the COVID-19 are unknown. In this review, we will focus on the recent information on genetics and pathogenesis of COVID-19 as well as its clinical presentation and potential treatments.

    Search related documents:
    Co phrase search for related documents
    • acceptable safety and active site: 1
    • acceptable safety and lopinavir ritonavir: 1, 2
    • accessory protein and active site: 1, 2
    • active site and liver injury: 1
    • active site and long time period: 1
    • active site and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute phase and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8
    • acute phase and admission severe disease: 1, 2, 3
    • acute phase and liver enzyme: 1, 2
    • acute phase and liver injury: 1, 2, 3, 4, 5, 6, 7, 8
    • acute phase and long time period: 1
    • acute phase and lopinavir ritonavir: 1, 2, 3, 4, 5
    • adaptive immune response and liver injury: 1
    • adaptive immune response and lopinavir ritonavir: 1
    • admission severe disease and liver injury: 1, 2, 3, 4, 5
    • admission severe disease and lopinavir ritonavir: 1, 2, 3
    • liver enzyme and lopinavir ritonavir: 1, 2, 3, 4
    • liver injury and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25